Penn Medicine Provider
Pulmonary Medicine
Daniel Joseph Dorgan, MD
5.0
(389)
Accepting new patients
Sees patients age 18 and up
Harron Lung Center Perelman

About me

  • Associate Program Director, Adult Cystic Fibrosis Program
  • Director, Adult Primary Ciliary Dyskinesia Program
  • Vice Chief of Clinical Affairs, Division of Pulmonary, Allergy, and Critical Care Medicine
  • Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)

Education and training

  • Medical School: University of Michigan
  • Residency: NewYork-Presbyterian/Columbia University Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

389 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
dr dorgan is very knowledgeable, easy to talk to, and eager to answer all questions and concerns
April 2025
5.0
5.0
dr.dorgan listens to my concerns and answers all my questions with patience and caring.
April 2025
5.0
5.0
i waited over 45 minutes for the appt. too long
April 2025
5.0
5.0
dr. dorgan is very thorough and just a nice guy.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Penn Medicine Rittenhouse Long-Term Acute Care Hospital
Dr. Dorgan is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Giannini HM, Lee C, Baston C, Dorgan D. A Diagnostic Sequence , N Engl J Med, 388: 2023,1702-1707


Hong G, Daniel SG, Lee JJ, Bittinger K, Glaser L, Mattei LM, Dorgan DJ, Hadjiliadis D, Kawut SM, Collman RG. Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis , J Cyst Fibros: 2023


Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study , J Cyst Fibros: 2023


O'Dea AL, Feng R, Glaser LJ, Kubrak C, Rubenstein RC, Dorgan DJ, Hadjiliadis D, Kawut SM, Hong G. The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis , Ann Am Thorac Soc: 2023


Lee IK, Jacome DA, Cho JK, Tu V, Young AJ, Dominguez T, Northrup JD, Etersque JM, Lee HS, Ruff A, Aklilu O, Bittinger K, Glaser LJ, Dorgan D, Hadjiliadis D, Kohli RM, Mach RH, Mankoff DA, Doot RK, Sellmyer MA Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim , The Journal of Clinical Investigation, 132(18): 2022,e156679


Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial , American Journal of Respiratory and Critical Care Medicine, 205(5): 2022,529-539


Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O’Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, on behalf of the SIMPLIFY Study Group Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials , The Lancet Respiratory Medicine: 2022


Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment , American Journal of Respiratory and Critical Care Medicine, 65(1): 2021,1295-1305


Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation , Journal of Cystic Fibrosis, 20(2): 2021,288-294


Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan D, Kohanski MA, Palmer JN, Adappa ND Impact of Novel CFTR Modulator on Sinonasal Quality of Life in Adult Patients with Cystic Fibrosis , International Forum of Allergy & Rhinology, 11(2): 2021,201-203